<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671682</url>
  </required_header>
  <id_info>
    <org_study_id>IAPEMS</org_study_id>
    <nct_id>NCT02671682</nct_id>
  </id_info>
  <brief_title>Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis</brief_title>
  <official_title>Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Christian Ludolph, Prof.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study investigates the efficacy and safety of immunoadsorption versus
      plasmapheresis in 60 patients with relapse in Multiple Sclerosis and Clinically isolated
      syndrome who do not fully recover after a high doses of intravenous corticosteroids.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>2 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol (EQ5D-5L)</measure>
    <time_frame>2 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>defined as share of patients who show an improvement of least 10% in MSFC (see Outcome 1) compared to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision</measure>
    <time_frame>4 weeks</time_frame>
    <description>defined as percentage of normal vision as measured by visual test according to EDSS standardized testing (see outcome 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visually Evoked Potentials (VEP; P100 latency)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatosensory Evoked Potentials (SEP; Medianus and Tibialis; N20-, P40-latency)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of Retinal Nerve Fiber Layer (RNFL) in Optical Coherence Tomography (OCT)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbaler Lern- und Merkfähigkeitstest (VLMT) score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSFC</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of Ganglion Cell Layer (GCL) in OCT</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test (SDMT) score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Clinically Isolated Syndrome</condition>
  <arm_group>
    <arm_group_label>Immunoadsorption</arm_group_label>
    <description>Immunoadsorption on 5 consecutive days with protein A columns and 2,5-fold patient's plasma volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmapheresis</arm_group_label>
    <description>Plasmapheresis on 5 consecutive days with 2l plasma exchange</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immunoadsorption</intervention_name>
    <arm_group_label>Immunoadsorption</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasmapheresis</intervention_name>
    <arm_group_label>Plasmapheresis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Eluate (Immunadsorption) and Plasma (Plasmapheresis)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with relapse of Multiple Sclerosis or Clinically Isolated Syndrome who do not
        fully recover after high doses of intravenous corticosteroids
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  relapse of Multiple Sclerosis or Clinically Isolated Syndrome (without complete
             remission after high dose steroid therapy)

          -  informed consent

          -  age ≥ 12 years old

        Exclusion Criteria:

          -  clinical or laboratory signs of infection

          -  intake of Angiotensin Converting Enzyme Inhibitor within 1 week prior to first
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Johannes Dorst, MD</last_name>
    <phone>+49(0)731 177</phone>
    <phone_ext>5285</phone_ext>
    <email>dorst_2001@yahoo.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert C Ludolph, MD, Prof.</last_name>
      <phone>+49-731-177-</phone>
      <phone_ext>1200</phone_ext>
      <email>albert.ludolph@rku.de</email>
    </contact>
    <investigator>
      <last_name>Albert C Ludolph, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Immunoadsorption</keyword>
  <keyword>Plasmapheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

